Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CollPlant Biotechnologies LtdCLGN · Entity 8153 | Deputy CEO and CFO | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CollPlant Biotechnologies Ltd
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 516,372 |
Reported balance
After 2026-09-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 510,372 · Balance 516,372 F1: The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date. F2: Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F3: The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.
F2: Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3: The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:05 UTC | CollPlant Biotechnologies Ltd CLGN · Entity 8153 | GrantOrdinary Shares | 510,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-098038 · ownership.xml · nonDerivative · entry 1 Rotem Eran · CIK 0001423145 · Deputy CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,372 F1 · security: The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date. F2 · shares: Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F3 · balance_after: The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.